logo
  Join        Login             Stock Quote

Elsevier Business Intelligence to Host 'IN3 East' at Hyatt Regency Boston on June 21-23, 2011

Wednesday, April 6, 2011 10:53 AM


'IN3 East' Is One of the East Coast's Biggest Annual Strategic Partnering and Investing Meetings for the Medtech Industry

BOSTON, MA -- (Marketwire) -- 04/06/11 -- Elsevier Business Intelligence, the medtech industry's leading provider of strategic partnership and investment conferences, announced today that it will host 'IN3East' on June 21-23, 2011, at the Hyatt Regency Boston.

IN3 events offer an unparalleled experience for emerging companies to meet and impress potential investors from many of the top-tier device companies and discerning healthcare investment firms from around the world.

One of the conference's highlights will be the keynote address by John Dempsey, Vice President, Strategic Customer Group, Johnson & Johnson -- "Leadership, Innovation and People Development: What Medical Device Executives Need to Know to Grow Their Businesses."

Investment firms and corporate acquirers that have attended IN3 events in the past or who have registered to attend IN3 East include: Abbott Ventures - Abingworth Management - Accuitive Medical Ventures - Advanced Technology Ventures - Aisling Capital - Alloy Ventures - Apposite Capital - Arboretum Ventures - ATEL Ventures - Bain Capital Ventures - Baird Venture Partners - Boston Scientific - Canaan Partners - Capricorn Venture Partners - Cardinal Health - Centocor Ortho Biotech - CHL Medical Partners - CitareTx Investment Partners I - Covidien - Credit Agricole Private Equity - De Novo Ventures - Delphi Ventures - Delta Partners - Domain Associates - Earlybird Venture Capital - Early Stage Partners - Edmond de Rothschild Investment Partners - Essex Woodlands Health Ventures - Fidelity Biosciences - Flybridge Capital Partners - Forbion Capital Partners - Fountain Healthcare Partners - Gilde Healthcare Partners - Hercules Technology Growth Capital - HLM Venture Partners - Hunza Ventures - Index Ventures - Intellectual Ventures - InterWest Partners - Kearny Venture Partners - Kimberly-Clark - Leader Ventures - LifeLine Ventures - Life Sciences Partners - Matignon Investissement & Gestion - Medtronic - MPM Capital - NBGI Ventures - New Enterprise Associates - New Leaf Ventures - Nexus Medical Partners - Onset Ventures - Pappas Ventures - Polaris - Prism Venture Partners - PTV Sciences - RCT BioVentures - River City Capital Funds - Safeguard Scientifics - Seroba-Kernel Life Sciences - Seventure Partners - Siemens Venture Capital - Skyline Ventures - Smith & Nephew Endoscopy - Sofimac Partners - Sofinnova Partners - Stryker Corporation - SV Life Sciences - Synergy Life Science Partners - Thomas McNerney & Partners - Trevi Health Ventures - US Venture Partners - Versant Ventures - Vivo Ventures - Wellington Partners - Western Technology Investment - Ysios Capital.

Additional upcoming IN3 event: IN3 Summit, Oct. 26-28, 2011, InterContinental Mark Hopkins, San Francisco. For more information about IN3 events, please contact: Kayleen Kell at +1-949-453-0071, or email K.Kell@Elsevier.com.

About Elsevier Business Intelligence
Elsevier Business Intelligence, an Elsevier company, is a global information supplier providing business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Elsevier Business Intelligence (www.elsevierbi.com) has offices in the U.S. in Bridgewater, N.J.; Norwalk, Conn.; Rockville, Md.; and Irvine, Calif.

About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (www.thelancet.com) and Cell (www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include Sciverse ScienceDirect (www.sciencedirect.com), Sciverse Scopus (www.scopus.com), Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and Nursing Consult (www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (www.scival.com) and MEDai's Pinpoint Review (www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact:
Ronald Trahan, APR
Ronald Trahan Associates Inc.
508-359-4005, x108

(Source: Market Wire )
(Source: Quotemedia)

Advertisement
Advertisement



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.